Publications by authors named "J A Zeevaart"
Kisspeptin (KISS1) and its cognate receptor (KISS1R) are implicated in the progression of various cancers. A gallium-68 labelled kisspeptin-10 (KP10), the minimal biologically active structure, has potential as a pan-tumour radiopharmaceutical for the detection of cancers. Furthermore, a lutetium-177 labelled KP10 could find therapeutic application in treating oncological diseases.
View Article and Find Full Text PDFBackground: The transplantation of hematopoietic stem and progenitor cells (HSPCs) or mesenchymal stromal/stem cells (MSCs) for the treatment of a wide variety of diseases has been studied extensively. A challenge with cell-based therapies is that migration to and retention at the target site is often difficult to monitor and quantify. Zirconium-89 (Zr) is a positron-emitting radionuclide with a half-life of 3.
View Article and Find Full Text PDFZirconium-89 (Zr) is a cyclotron-produced positron-emitting radioisotope with a half-life of 3.27 days, which makes delayed or longitudinal imaging possible. It is a superior isotope for tracking particles over several days at a high sensitivity, resolution, and specificity.
View Article and Find Full Text PDFArticle Synopsis
- Nuclear medicine infection imaging typically uses technetium-99m radiolabelled leukocytes with SPECT, but zirconium-89 offers improved sensitivity and image quality through PET technology, allowing delayed imaging for better accuracy in locating infections.
- A study explored the application of zirconium-labelled leukocytes for infection imaging in patients, comparing results from PET and SPECT to assess the quality and distribution of these radiolabelled cells.
- Results showed successful labelling with high efficiency and viability of the zirconium-labelled leukocytes, indicating potential benefits over traditional imaging methods.
This research presents the development of positron emission tomography (PET) radiotracers for detecting Mycobacterium tuberculosis (MTB) for the diagnosis and monitoring of tuberculosis. Two phage display-derived peptides with proven selective binding to MTB were identified for development into PET radiopharmaceuticals: H8 (linear peptide) and PH1 (cyclic peptide). We sought to functionalize H8/PH1 with NODASA, a bifunctional chelator that allows complexation of PET-compatible radiometals such as gallium-68.
View Article and Find Full Text PDF